Gene therapy for stroke: 2006 overview

Yi Chu, Jordan D Miller, Donald D. Heistad

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Gene therapy is a promising approach for treatment of stroke and other cerebrovascular diseases, although it may take many years to realize. Gene therapy could occur prior to a stroke (eg, to stabilize atherosclerotic plaques) and/or following a stroke (eg, to prevent vasopasm after subarachnoid hemorrhage [SAH] or reduce injury to neurons by ischemic insult). We have transferred the gene coding for vasoactive calcitonin gene-related peptide via cerebrospinal fluid, and demonstrated attenuation of vasospasm after SAH. Transfer of neuroprotective genes or small interfering RNA for neurotoxic genes has good potential for ischemic stroke. In this brief report, we review recent developments in experimental gene therapy for stroke. Fundamental advances, including development of safer, more specific gene transfer vectors, are discussed.

Original languageEnglish (US)
Pages (from-to)19-24
Number of pages6
JournalCurrent Hypertension Reports
Volume9
Issue number1
DOIs
StatePublished - Mar 2007
Externally publishedYes

Fingerprint

Genetic Therapy
Stroke
Subarachnoid Hemorrhage
Genes
Cerebrovascular Disorders
Investigational Therapies
Calcitonin Gene-Related Peptide
Atherosclerotic Plaques
Small Interfering RNA
Cerebrospinal Fluid
Neurons
Wounds and Injuries
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Gene therapy for stroke : 2006 overview. / Chu, Yi; Miller, Jordan D; Heistad, Donald D.

In: Current Hypertension Reports, Vol. 9, No. 1, 03.2007, p. 19-24.

Research output: Contribution to journalArticle

Chu, Yi ; Miller, Jordan D ; Heistad, Donald D. / Gene therapy for stroke : 2006 overview. In: Current Hypertension Reports. 2007 ; Vol. 9, No. 1. pp. 19-24.
@article{500ec1f0ebe94629a2790b352c1291ab,
title = "Gene therapy for stroke: 2006 overview",
abstract = "Gene therapy is a promising approach for treatment of stroke and other cerebrovascular diseases, although it may take many years to realize. Gene therapy could occur prior to a stroke (eg, to stabilize atherosclerotic plaques) and/or following a stroke (eg, to prevent vasopasm after subarachnoid hemorrhage [SAH] or reduce injury to neurons by ischemic insult). We have transferred the gene coding for vasoactive calcitonin gene-related peptide via cerebrospinal fluid, and demonstrated attenuation of vasospasm after SAH. Transfer of neuroprotective genes or small interfering RNA for neurotoxic genes has good potential for ischemic stroke. In this brief report, we review recent developments in experimental gene therapy for stroke. Fundamental advances, including development of safer, more specific gene transfer vectors, are discussed.",
author = "Yi Chu and Miller, {Jordan D} and Heistad, {Donald D.}",
year = "2007",
month = "3",
doi = "10.1007/s11906-007-0005-7",
language = "English (US)",
volume = "9",
pages = "19--24",
journal = "Current Hypertension Reports",
issn = "1522-6417",
publisher = "Current Medicine Group",
number = "1",

}

TY - JOUR

T1 - Gene therapy for stroke

T2 - 2006 overview

AU - Chu, Yi

AU - Miller, Jordan D

AU - Heistad, Donald D.

PY - 2007/3

Y1 - 2007/3

N2 - Gene therapy is a promising approach for treatment of stroke and other cerebrovascular diseases, although it may take many years to realize. Gene therapy could occur prior to a stroke (eg, to stabilize atherosclerotic plaques) and/or following a stroke (eg, to prevent vasopasm after subarachnoid hemorrhage [SAH] or reduce injury to neurons by ischemic insult). We have transferred the gene coding for vasoactive calcitonin gene-related peptide via cerebrospinal fluid, and demonstrated attenuation of vasospasm after SAH. Transfer of neuroprotective genes or small interfering RNA for neurotoxic genes has good potential for ischemic stroke. In this brief report, we review recent developments in experimental gene therapy for stroke. Fundamental advances, including development of safer, more specific gene transfer vectors, are discussed.

AB - Gene therapy is a promising approach for treatment of stroke and other cerebrovascular diseases, although it may take many years to realize. Gene therapy could occur prior to a stroke (eg, to stabilize atherosclerotic plaques) and/or following a stroke (eg, to prevent vasopasm after subarachnoid hemorrhage [SAH] or reduce injury to neurons by ischemic insult). We have transferred the gene coding for vasoactive calcitonin gene-related peptide via cerebrospinal fluid, and demonstrated attenuation of vasospasm after SAH. Transfer of neuroprotective genes or small interfering RNA for neurotoxic genes has good potential for ischemic stroke. In this brief report, we review recent developments in experimental gene therapy for stroke. Fundamental advances, including development of safer, more specific gene transfer vectors, are discussed.

UR - http://www.scopus.com/inward/record.url?scp=34047247335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047247335&partnerID=8YFLogxK

U2 - 10.1007/s11906-007-0005-7

DO - 10.1007/s11906-007-0005-7

M3 - Article

C2 - 17362667

AN - SCOPUS:34047247335

VL - 9

SP - 19

EP - 24

JO - Current Hypertension Reports

JF - Current Hypertension Reports

SN - 1522-6417

IS - 1

ER -